Balance Sheet Components (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
| Balance Sheet Components [Abstract] |
|
| Schedule of Inventory |
Inventory consists of the following (in thousands): | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | Raw materials | $ | 2,613 | | | $ | 2,898 | | | Work in progress | 20,139 | | | 18,473 | | | Finished goods | 3,017 | | | 3,516 | | | Total inventory | $ | 25,769 | | | $ | 24,887 | |
|
| Schedule of Finite Lived Intangible Assets |
The components of the Company’s intangible assets were as follows (in thousands, except for weighted-average remaining amortization period): | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2026 | | Gross Carrying Value | | Accumulated Amortization | | Net Carrying Amount | | Weighted-Average Remaining Amortization Period (Years) | | Commercial milestones | $ | 94,000 | | | $ | (15,527) | | | $ | 78,473 | | | 11.1 | | Developed technology | 226,620 | | | (57,759) | | | 168,861 | | | 9.3 | | Assembled workforce | 970 | | | (916) | | | 54 | | | 0.2 | | Total intangible assets | $ | 321,590 | | | $ | (74,202) | | | $ | 247,388 | | | 9.8 |
| | | | | | | | | | | | | | | | | | | | | | | | | December 31, 2025 | | Gross Carrying Value | | Accumulated Amortization | | Net Carrying Amount | | Weighted-Average Remaining Amortization Period (Years) | | Commercial milestones | $ | 94,000 | | | $ | (11,660) | | | $ | 82,340 | | | 11.5 | | Developed technology | 226,620 | | | (48,255) | | | 178,365 | | | 9.7 | | Assembled workforce | 970 | | | (754) | | | 216 | | | 0.7 | | Total intangible assets | $ | 321,590 | | | $ | (60,669) | | | $ | 260,921 | | | 10.3 |
|
| Schedule of Estimated Future Amortization Expense Associated with Intangible Assets |
The following table summarizes the estimated future amortization expense associated with the Company’s intangible assets as of June 30, 2026 (in thousands): | | | | | | | Amount | | 2026 (remaining six months) | $ | 13,425 | | | 2027 | 26,742 | | | 2028 | 26,742 | | | 2029 | 26,742 | | | 2030 | 26,742 | | | Thereafter | 126,995 | | | $ | 247,388 | |
|
| Schedule of Accrued Expenses |
Accrued expenses consist of the following (in thousands): | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | Accrued sales deductions and other | $ | 62,501 | | | $ | 51,375 | | | Accrued compensation and related benefits | 28,389 | | | 47,276 | | | Accrued clinical trials | 22,872 | | | 13,959 | | | Accrued professional service fees | 21,886 | | | 17,292 | | | Accrued contract manufacturing and non-clinical costs | 17,670 | | | 8,721 | | | Accrued royalties payable | 16,204 | | | 16,208 | | | Operating lease liabilities, current | 2,405 | | | 2,139 | | | Accrued loss on firm purchase commitments | 2,107 | | | 2,107 | | | Accrued interest | 527 | | | 2,108 | | | Accrued milestone payment | — | | | 35,000 | | | Total accrued expenses and other current liabilities | $ | 174,561 | | | $ | 196,185 | |
|
| Schedule of Other Noncurrent Liabilities |
Other liabilities consist of the following (in thousands): | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | Noncurrent accrued sales deductions | $ | 8,882 | | | $ | 3,586 | | | Noncurrent accrued loss on firm purchase commitments | 1,425 | | | 1,425 | | | Other | 610 | | | — | | | Total other liabilities | $ | 10,917 | | | $ | 5,011 | |
|